Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction

被引:23
|
作者
Zhuang, Chunlin [1 ]
Miao, Zhenyuan [1 ]
Zhu, Lingjian [1 ]
Zhang, Yongqiang [1 ]
Guo, Zizhao [1 ]
Yao, Jianzhong [1 ]
Dong, Guoqiang [1 ]
Wang, Shengzheng [1 ]
Liu, Yang [1 ]
Chen, Hai [1 ]
Sheng, Chunquan [1 ]
Zhang, Wannian [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
关键词
p53-MDM2; Small molecule inhibitors; Thio-benzodiazepine; Antitumor activity; IN-VIVO; P53; MDM2; ANTAGONISTS; DISCOVERY; DRUG; ACTIVATION; STRATEGY; DESIGN; CANCER;
D O I
10.1016/j.ejmech.2011.09.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of thio-benzodiazepine p53-MDM2 inhibitors were designed and synthesized based on the principle of bioisosterism. Most of the thio-benzodiazepines had nanomolar to micromolar affinity toward MDM2. Particularly, compounds 8a (K-i = 0.52 mu M) and 8f (K-i = 0.32 mu M) showed binding activity comparable to the positive drug nutlin-3a (K-i = 0.23 mu M). Meanwhile, compound 8j exhibited excellent antitumor activity against the U-2 OS human osteosarcoma cell line with an IC50 value of 1.06 mu M, which was about 23 times higher than that of nutlin-3a. The docking model also successfully predicted that this class of compounds mimicked three p53 critical residues binding to MDM2. The thio-benzodiazepines represent a promising class of non-peptide inhibitors of the p53-MDM2 interaction. (C) 2011 Published by Elsevier Masson SAS.
引用
收藏
页码:5654 / 5661
页数:8
相关论文
共 50 条
  • [31] Flexibility is important for inhibition of the MDM2/p53 protein-protein interaction by cyclic β-hairpins
    Danelius, Emma
    Pettersson, Mariell
    Bred, Matilda
    Min, Jaeki
    Waddell, M. Brett
    Guy, R. Kiplin
    Grotli, Morten
    Erdelyi, Mate
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 14 (44) : 10386 - 10393
  • [32] Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
    Zanjirband, Maryam
    Rahgozar, Soheila
    CURRENT DRUG TARGETS, 2019, 20 (11) : 1091 - 1111
  • [33] Small-molecule MDM2-p53 inhibitors: recent advances
    Zhang, Bian
    Golding, Bernard T.
    Hardcastle, Ian R.
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (05) : 631 - 645
  • [34] Patented inhibitors of p53-Mdm2 interaction (2006-2008)
    Weber, Lutz
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (02) : 179 - 191
  • [35] Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2
    Wang, Weisi
    Lv, Dan
    Qiu, Ni
    Zhang, Lei
    Hu, Chunqi
    Hu, Yongzhou
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (11) : 2886 - 2894
  • [36] Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity
    Brandao, Pedro
    Loureiro, Joana B.
    Carvalho, Sylvie
    Hamadou, Meriem Hadjer
    Cravo, Sara
    Moreira, Joana
    Pereira, Daniela
    Palmeira, Andreia
    Pinto, Madalena
    Saraiva, Lucilia
    Cidade, Honorina
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 156 : 711 - 721
  • [37] Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction
    Lin, Zhitong
    Liu, Chen
    Yan, Ziqin
    Cheng, Jing
    Wang, Xiancheng
    Zhou, Feilong
    Lyu, Xilin
    Zhang, Shiyan
    Zhang, Daizhou
    Meng, Xiangjing
    Zhao, Yujun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 270
  • [38] Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction
    Plante, Jeffrey P.
    Burnley, Thomas
    Malkova, Barbora
    Webb, Michael E.
    Warriner, Stuart L.
    Edwards, Thomas A.
    Wilson, Andrew J.
    CHEMICAL COMMUNICATIONS, 2009, (34) : 5091 - 5093
  • [39] p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
    Nayak, Surendra Kumar
    Khatik, Gopal L.
    Narang, Rakesh
    Monga, Vikramdeep
    Chopra, Harish Kumar
    CURRENT CANCER DRUG TARGETS, 2018, 18 (08) : 749 - 772
  • [40] Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic
    Carry, Jean-Christophe
    Garcia-Echeverria, Carlos
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2480 - 2485